Human Retroviral Infections in the Tropics

Tropical Infectious Diseases

Volumn 1, Issue , 2006, Pages 852-883

  Reynolds, Steven J ^a,b   Bessong, Pascal O ^c,d   Quinn, Thomas C ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^c UNIVERSITY OF VENDA   (South Africa)

^d UNIVERSITY OF VIRGINIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 36448978595     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-443-06668-9.50081-8     Document Type: Chapter

References (309)

1. Gottlieb MS, Schroff R, Schranker HM, et al. Pneumocystis carinii pneumonia and mucosal candidiasis in previously healthy homosexual men. N Engl J Med 1981, 305:1430.
2. Masur H, Michelis MA, Greene JB, et al. An outbreak of community-acquired Pneumocystis carinii pneumonia: initial manifestation of cellular immune dysfunction. N Engl J Med 1981, 305:1431.
3. Siegal FP, Lopez C, Hammer GS, et al. Severe acquired immunodeficiency in male homosexuals, manifested by chronic perianal ulcerative herpes simplex lesions. N Engl J Med 1981, 305:1444.
4. Pape JW, Liautaud B, Thomas F, et al. Characteristics of the acquired immunodeficiency syndrome in Haiti. Ann Intern Med 1985, 103:674.
5. Piot P, Quinn TC, Taelman H, et al. Acquired immunodeficiency syndrome in a heterosexual population in Zaire. Lancet 1984, 2:65.
6. Quinn TC, Mann JM, Curran JW, et al. AIDS in Africa: an epidemiologic paradigm. Science 1986, 234:955.
7. Barre-Sinoussi F, Chermann JC, Rey F, et al. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science 1983, 220:868.
8. Gallo RC, Salahuddin SZ, Popovic M, et al. Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS. Science 1984, 224:500.
9. Mann JM, Chin J, Piot P, et al. The international epidemiology of AIDS. Sci Am 1988, 10:82.
10. Quinn TC The global burden of the HIV pandemic. Lancet 1996, 348:99.
11. 2004 Report on the global AIDS epidemic 2004, UNAIDS, UNAIDS, Geneva.
12. Kaplan JE, Hu DJ, Holmes KK, et al. Preventing opportunistic infections in human immunodeficiency virus-infected persons: implications for the developing world. Am J Trop Med Hyg 1996, 55:1.
13. Grant AD, Kaplan JE, DeCock KM Preventing opportunistic infections among human immunodeficiency virus-infected adults in African countries. Am J Trop Med Hyg 2001, 65:810.
14. Barre-Sinoussi F, Cherman J-C, Ray F, et al. Isolation of a T-lympho-tropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science 1993, 224:868.
15. Gallo RC, Salahuddin SZ, Popovic M, et al. Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS. Science 1984, 224:500.
16. Froland SS, Jenum P, Lindboe CF, et al. HIV-1 infection in a Norwegian family before 1970. Lancet 1988, 1:1344.
17. Bryceson A, Tomkins A, Ridley D, et al. HIV-2-associated AIDS in the 1970s. Lancet 1988, 2:221.
18. Nahmias AJ, Weiss J, Yao X, et al. Evidence for human infection with an HTLV III/LAV-like virus in Central Africa: 1959. Lancet 1986, 1:1279.
19. Getchell JP, Hicks DR, Svinivasan A, et al. Human immunodeficiency virus isolated from a serum sample collected in 1976 in Central Africa. J Infect Dis 1987, 156:833.
20. Nzilambi N, DeCock KM, Forthal DN, et al. The prevalence of infection with human immunodeficiency virus over a 10-year period in rural Zaire. N Engl J Med 1988, 318:276.
21. Srinivasan A, York D, Butler D, et al. Molecular characterization of HIV-1 isolated from a serum collected in 1976: nucleotide sequence comparison to recent isolates and generation of hybrid HIV AIDS. Res Hum Retroviruses 1989, 5:121.
22. Meyers G, Pavlakis GN Evolutionary potential of complex retroviruses. The Retroviridae 1992, Plenum Press, New York. J. Levy (Ed.).
23. English RV, Nelson P, Johnson CM, et al. Development of clinical disease in cats experimentally infected with feline immunodeficiency virus. J Infect Dis 1994, 170:543.
24. Gonda MA, Luther DG, Fong SE, et al. Bovine immunodeficiency virus: molecular biology and virus-host interactions. Virus Res 1994, 32:155.
25. Zink MC, Johnson LK Pathobiology of lentivirus infections in sheep and goats. Virus Res 1994, 32:139.
26. Sellon DC, Fuller FJ, McGuire TC The immunopathogenesis of equine infectious anemia virus. Virus Res 1994, 32:111.
27. Issel CJ, Foil LD Studies on equine infectious anemia virus transmission by insects. J Am Vet Med Assoc 1984, 184:293.
28. Hirsch VM, Dapolito GA, Goldstein S, et al. A distinct African lentivirus from Sykes' monkeys. J Virol 1993, 67:1517.
29. Jin MJ, Hui H, Robertson DL, et al. Mosaic genome structure of simian immunodeficiency virus from West African green monkeys. EMBO J 1994, 14:2935.
30. Daniel MD, Letvin NL, King NW, et al. Isolation of a T-cell tropic HTLV-III-like retrovirus from macaques. Science 1985, 228:1201.
31. Kanki PJ, McLane MF, King NW, et al. Serologic identification and characterization of a macaque T-lymphotropic retrovirus closely related to HTLV-III. Science 1985, 228:1199.
32. Gurtler LG, Hauser PH, Eberle J, et al. A new subtype of human immunodeficiency virus type 1 (MVP-5180) from Cameroon. J Virol 1994, 68:1581.
33. Vanden Haesevelde M, DeCourt J-L, De Leys RJ, et al. Genomic cloning and complete sequence analysis of a highly divergent African human immunodeficiency virus isolate. J Virol 1994, 68:1586.
34. Simon F, Mauclere P, Roques P, et al. Identification of a new human immunodeficiency virus type 1 distinct from group M and O. Nature Med 1998, 4:1032.
35. Roques P, Robertson DL, Souquière S, et al. Phylogenetic characteristics of three new HIV-1 N strains and implications for the origin of group N. AIDS 2004, 18:1371.
36. Huet T, Cheynier R, Meyerhans A, et al. Genetic organization of a chimpanzee lentivirus related to HIV-1. Nature 1990, 345:356.
37. Louwagie J, McCutchan FE, Peeters M, et al. Phylogenetic analysis of gag genes from 70 international HIV-1 isolates provides evidence for multiple genotypes. AIDS 1993, 7:769.
38. Louwagie J, Janssens W, Mascola J, et al. Genetic diversity of the envelope glycoprotein from HIV-1 isolates of African origin. J Virol 1995, 69:263.
39. Roques P, Menu E, Narwa R, et al. An unusual HIV type 1env sequence embedded in a mosaic virus from Cameroon: identification of a new clade. European Network on the study of in utero transmission of HIV-1. AIDS Res Hum Retroviruses 1999, 15:1585.
40. Robertson DL, Anderson JP, Bradac JA, et al. HIV-1 nomenclature proposal. Science 2000, 288:56.
41. Sharp PM, Robertson DL, Gao F, et al. Origins and diversity of human immunodeficiency viruses. AIDS 1994, 8(suppl):S27.
42. Gao F, Robertson DL, Morrison SG, et al. The heterosexual human immunodeficiency virus type 1 in Thailand is caused by an intersubtype (A/E) recombinant of African origin. J Virol 1996, 70:7013.
43. Kostrikis LG, Bagdades E, Cao Y, et al. Genetic analysis of human immunodeficiency virus type 1 strains from patients in Cyprus: identification of a new subtype designated I. J Virol 1995, 71:7088.
44. Gao F, Robertson DL, Carruthers CD, et al. An isolate of human immunodeficiency virus type 1 originally classified as subtype I represents a complex mosaic comprising three different group M subtypes (A, G and I). J Virol 1998, 72:10234.
45. Nasioulas G, Paraskovis D, Magiorkinis E, et al. Molecular analysis of the full-length genome of HIV type 1 subtype I: evidence of A/G/I recombination. AIDS Res Hum Retroviruses 1999, 15:745.
46. Carr JK, Salimen MO, Albert J, et al. Full genome sequences of human immunodeficiency virus type 1 subtypes G and A/G intersubtype recombinants. Virology 1998, 247:22.
47. Carr JK, Salimen MO, Koch C, et al. Full-length sequence and mosaic structure of a human immunodeficiency virus type 1 isolate from Thailand. J Virol 1999, 70:5935.
48. Liitsola K, Tashikinova I, Laukkenen T, et al. HIV-1 genetic subtype A/B recombinant strain causing an explosive epidemic in injecting drug users in Kaliningrad. AIDS 1998, 12:1907.
49. Morrow JW, Homsy J, Eichberg JW, et al. Long-term observation of baboons, rhesus monkeys, and chimpanzees inoculated with HIV and given periodic immunosuppressive treatments. AIDS Res Hum Retroviruses 1989, 5:233.
50. Otten RA, Brown BG, Simon M, et al. Differential replication and pathogenic effects of HIV-1 and HIV-2 in Macaca nemestrina. AIDS 1994, 8:297.
51. Gartner S, Liu Y, Polonis V, et al. Adaptation of HIV-1 to pigtailed macaques. J Med Primatol 1994, 23:155.
52. Letvin N, Li J, Halloran M, et al. Prior infection with a nonpathogenic chimeric simian-human immunodeficiency virus does not efficiently protect macaques against challenge with simian immunodeficiency virus. J Virol 1995, 69:4569.
53. Feline immunodeficiency virus xenoinfection: the role of chemokine receptors and envelop diversity. J Virol 2000, 76:3626. Johnston JB, Power C.
54. Hahn BH, Shaw GM, de Cock KM, et al. AIDS as a zoonosis: scientific and public health implications. Science 2000, 287:607.
55. Robertson DL, Sharp PM, McCutchan FE, et al. Recombination in HIV-1 (letter). Nature 1995, 374:124.
56. Meyers GB, Korber BH, Hahn K-T Human Retroviruses and AIDS: A Compilation and Analysis of Nucleic Acid and Amino Acid Sequences 1995, Los Alamos National Laboratory, Los Alamos, N.M.
57. Cullen BR Human immunodeficiency virus as a prototypic complex retrovirus. J Virol 1991, 65:1053.
58. Lasky LA, Nakamura G, Smith DH, et al. Delineation of a region of the human immunodeficiency virus type 1 gp120 glycoprotein critical for interaction with the CD4 receptor. Cell 1987, 50:975.
59. Doranz BJ, Berson JF, Rucker J, et al. Chemokine receptors as fusion cofactors for human immunodeficiency virus type 1 (HIV-1). Immunol Res 1997, 16:15.
60. Ji J, Loeb LA Fidelity of HIV-1 reverse transcriptase copying RNA in vitro. Biochemistry 1992, 31:954.
61. Bukrinsky MI, Sharova N, McDonald TL, et al. Association of integrase, matrix, and reverse transcriptase antigens of human immunodeficiency virus type 1 with viral nucleic acids following acute infection. Proc Natl Acad Sci USA 1993, 90:6125.
62. * in mediating the selective incorporation of tRNA (Lys) into human immunodeficiency virus type 1 particles. J Virol 1994, 68:2065.
63. Dvorin JD, Bell P, Maul GG, et al. Reassessment of the roles of integrase and the central DNA flap in human immunodeficiency virus type 1 nuclear import. J Virol 2002, 76:12087.
64. Sherman MP, Greene WC Slipping through the door: HIV entry into the nucleus. Microbes Infect 2002, 4:67.
65. Sherman MP, DeNoronha CMC, Williams SA, et al. Insights into the biology of HIV-1 viral protein r. DNA Cell Biol 2002, 21:679.
66. Wiskerchen M, Muesing MA Human immunodeficiency virus type 1 integrase: effects of mutations on viral ability to integrate, direct viral gene expression from unintegrated viral DNA templates, and sustain viral propagation in primary cells. J Virol 1995, 69:379.
67. Shiramizu B, Herndier BG, McCrath MS Identification of a common clonal human immunodeficiency virus integration site in human immunodeficiency virus-associated lymphomas. Cancer Res 1994, 54:2069.
68. Bielinska A, Krasnow S, Nabel GJ NF-kB-mediated activation of the human immunodeficiency virus enhancer: site of transcriptional initiation is independent of the TATA box. J Virol 1989, 63:4097.
69. Lu Y, Stenzel M, Sodroski JG, Haseltine WA Effects of long terminal repeat mutations on human immunodeficiency virus type 1 replication. J Virol 1989, 63:4115.
70. Olsen HS, Rowen CA Contribution of the TATA motif to tat-mediated transcriptional activation of human immunodeficiency virus gene expression. J Virol 1992, 66:5594.
71. Malim MH, Tiley L, McCarn D, et al. HIV-1 structural gene expression required binding of the Rev trans-activator to its RNA target sequence. Cell 1990, 60:675.
72. Malim MH, Bohnlein S, Hauber J, et al. Functional dissection of the HIV-1 rev trans-activator: derivation of a trans-dominant repressor of rev function. Cell 1989, 58:205.
73. Dorfman T, Burkovsky A, Ohagen A, et al. Functional domains of the capsid protein of human immunodeficiency virus type 1. J Virol 1994, 68:8180.
74. South TL, Blake PR, Sowder RC, et al. The nucleocapsid protein isolated from HIV-1 particles binds zinc and forms retroviral-type zinc fingers. Biochemistry 1990, 29:7786.
75. Earl PL, Doms RW, Moss B Oligomeric structure of the human immunodeficiency virus type 1 envelope glycoproteins. Proc Natl Acad Sci USA 1990, 87:648.
76. Poumbourios P, el Ahmar W, McPhee DA, et al. Determinants of human immunodeficiency virus type 1 envelope glycoprotein oligomeric structure. J Virol 1995, 69:1209.
77. Pantaleo G, Fauci AS New concepts in the immunopathogenesis of HIV infection. Annu Rev Immunol 1995, 13:487.
78. Pantaleo G, Graziosi C, Demarest JF, et al. HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease. Nature 1993, 362:355.
79. Sullivan N, Sun Y, Li J, et al. Replicative function and neutralization sensitivity of envelope glycoproteins from primary and T-cell line-passaged human immunodeficiency virus type 1 isolates. J Virol 1995, 69:4413.
80. More JP Back to primary school. Nature 1995, 376:115.
81. Milich L, Margolin BH, Swanstrom R Patterns of amino acid variability in NSI-like and SI-like V3 sequences and a linked change in the CD4-binding domain of HIV-1 env protein. Virology 1997, 239:108.
82. Jansson M, Backstrom E, Scarlatti G, et al. Length variation of glycoprotein 120 V2 region in relation to biological phenotypes and coreceptor usage of primary HIV type 1 isolates. AIDS Res Hum Retroviruses 2001, 17:1405.
83. Salvatori F, Scarlatti G HIV type 1 chemokine receptor usage in mother-to-child transmission. AIDS Res Hum Retroviruses 2001, 17:925.
84. Libert F, Cochaux P, Beckman G, et al. The 8ccr5 mutation conferring protection against HIV-1 in caucasian populations has a single and recent origin in North-eastern Europe. Hum Mol Genet 1998, 7:399.
85. Berger EA, Murphy PM, Farber JM Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism and disease. Ann Rev Immunol 1999, 17:657.
86. Moore JP, Kitchen SG, Pugach P, et al. The CCR5 and CXCR4 coreceptors-central to understanding the transmission and pathogenesis of human immunodeficiency virus type 1 infection. AIDS Res Hum Retroviruses 2004, 20:111.
87. Lopalco L, Barassi C, Pastori C, et al. CCR5-reactive antibodies in seronegative partners of HIV-seropositive individuals down modulate surface CCR5 in vivo and neutralize the infectivity of R5 strains of HIV-1 in vitro. J Immunol 2000, 164:3426.
88. Cullen BR A new entry route for HIV. Nature Med 2001, 7:20.
89. Robertson DL, Hahn BH, Sharp PM Recombination of AIDS viruses. J Mol Evol 1995, 40:249.
90. Lozovskaya ER, Hartl DL, Petrov DA Genomic regulation of transposable elements in Drosophila. Curr Opin Genet Dev 1995, 5:768.
91. Leib-Mösch C, Seifarth W Evolution and biological significance of human retroelements. Virus Genes 1995, 11:133.
92. Mountz JD, Talal N Retroviruses, apoptosis and autogenes. Immunol Today 1993, 14:532.
93. Nakagawa K, Harrison LC The potential roles of endogenous retroviruses in autoimmunity. Immunol Rev 1996, 152:193.
94. Franchini G, Reitz MS Phylogenesis and genetic complexity of the nonhuman primate retroviridae. AIDS Res Hum Retroviruses 1994, 10:1047.
95. Gardner MB The history of simian AIDS. J Med Primatol 1996, 25:148.
96. Aguzzi A The foamy virus family: molecular biology, epidemiology and neuropathology. Biochim Biophys Acta 1993, 1155:1.
97. Doolittle RF, Feng DF, McClure MA, et al. Retrovirus phylogeny and evolution. Curr Top Microbiol Immunol 1990, 157:1.
98. Gessain A, de Thé G Geographic and molecular epidemiology of primate T lymphotropic retroviruses: HTLV-I, HTLV-II, STLV-I, STLV-PP, and PTLV-L. Adv Virus Res 1996, 47:377.
99. Uchiyama T ATL and HTLV-I: in vivo cell growth of ATL cells. J Clin Immunol 1996, 16:305.
100. Ijichi S, Nakagawa M, Umehara F, et al. HAM/TSP: Recent perspectives in Japan. J Acquir Immune Defic Syndr Hum Retrovirol 1996, 13(suppl 1):S26.
101. Yamashita M, Ido E, Miura T, et al. Molecular epidemiology of HTLV-I in the world. J Acquir Immune Defic Syndr Hum Retrovirol 1996, 13(suppl 1):S124.
102. Yamaguchi K Human T-lymphotropic virus type I in Japan. Lancet 1994, 343:213.
103. Ruff AJ Breastmilk, breastfeeding, and transmission of viruses to the neonate. Semin Perinatol 1994, 18:510.
104. Taylor GP The epidemiology of HTLV-I in Europe. J Acquir Immune Defic Syndr Hum Retrovirol 1996, 13(suppl 1):S8.
105. Piot P, Plummer FS, Mhalu JL, et al. AIDS: an international perspective. Science 1988, 239:573.
106. Haverkos HW, Quinn TC The third wave: HIV infection among heterosexuals in the United States and Europe. Int J STD AIDS 1995, 6:227.
107. Available at. Accessed 9/20/04. http://www.nacoonline.org/factsnfigures/hivestimates2003.pdf.
108. UNAIDS: The status and trends of the global HIV/AIDS pandemic. Geneva, UNAIDS, July 5-6, 1996.
109. Mann J, Tarantola D The state of the pandemic and its impact. AIDS in the World 1996, 2. Oxford University Press, London. J. Mann, D. Tarantola (Eds.).
110. Padian NS Heterosexual transmission of acquired immunodeficiency syndrome: international perspectives and national projections. Rev Infect Dis 1987, 9:947.
111. Piot P, Goeman J, Laga M The epidemiology of HIV and AIDS in Africa. AIDS in Africa 1994, 157. Raven Press, New York. M. Essex, S. Mboup, P. Kanki (Eds.).
112. Piot P, Kreiss JK, Ndinya-Achola JO, et al. Heterosexual transmission of HIV. AIDS 1988, 2:1.
113. Quinn TC, Fauci AS The changing demography of AIDS: emergence of heterosexual transmission. Harrison's Principles of Internal Medicine 1994, 1. McGraw-Hill, New York. 13th ed. K.J. Isselbacher, E. Braunwald, J.D. Wilson (Eds.).
114. Quinn TC Population migration and the spread of types 1 and 2 human immunodeficiency viruses. Proc Natl Acad Sci USA 1994, 91:2407.
115. Flemming DT, Wasserheit JN From epidemiological synergy to public health policy and practice: the contribution of other sexually transmitted diseases to sexual transmission of HIV infection. Sex Transm Infect 1999, 75:3.
116. Latif AS, Katzenstein DA, Bassett MT, et al. Genital ulcers and transmission of HIV among couples in Zimbabwe. AIDS 1989, 3:519.
117. Laga M, Manoka A, Kivuvu M, et al. Non-ulcerative sexually transmitted diseases as risk factors for HIV-1 transmission in women: results from a cohort study. AIDS 1993, 7:95.
118. Laga M, Diallo MO, Buve A Inter-relationship of sexually transmitted diseases and HIV: where are we now?. AIDS 1994, 8(suppl 1):S119.
119. Quinn TC, Glasser D, Cannon RO, et al. Human immunodeficiency virus infection among patients attending clinics for sexually transmitted diseases. N Engl J Med 1988, 318:197.
120. Otten M, Zaidi AA, Peterman TA, et al. High rate of HIV seroconversion among patients attending urban sexually transmitted disease clinics. AIDS 1994, 8:549.
121. Quinn TC Association of sexually transmitted diseases and infection with the human immunodeficiency virus: biological cofactors and markers of behavioural interventions. Int J STD AIDS 1996, 7:17.
122. Reynolds SJ, Risbud AR, Shepherd ME, et al. Recent herpes simplex virus type 2 infection and the risk of human immunodeficiency virus type 1 acquisition in India. J Infect Dis 2003, 187:1513.
123. An Overview of Selected Curable Sexually Transmitted Diseases 1995, Global Programme on AIDS, World Health Organization, Geneva.
124. Peckham C, Gibb D Mother-to-child transmission of the human immunodeficiency virus. N Engl J Med 1995, 333:298.
125. Trends and Patterns of HIV and AIDS Infection in Selected Developing Countries. Research Note No. 14: Country Profiles June, 1994, U.S. Bureau of Census, Department of State, Washington, D.C.
126. Rates of mother-to-child transmission of HIV-1 in Africa, America, and Europe: Results from 13 perinatal studies. J Acquir Immune Defic Syndr Hum Retrovirol 1995, 8:1495. The Working Group on Mother-to-Child Transmission of HIV.
127. St Louis M, Kamenga M, Brown C, et al. Risk for perinatal HIV-1 transmission according to maternal immunologic, virologic, and placental factors. JAMA 1993, 269:2853.
128. Burns DN, Landesman S, Muenz LR, et al. Cigarette smoking, premature rupture of membranes, and vertical transmission of HIV-1 among women with low CD4- levels. J Acquir Immune Defic Syndr Hum Retrovirol 1994, 7:718.
129. Weisner B, Nachman S, Tropper P, et al. Quantitation of human immunodeficiency virus type 1 during pregnancy: relationship of viral titer to mother-to-child transmission and stability of viral load. Proc Natl Acad Sci USA 1994, 91:8037.
130. Semba RLD, Miotti PG, Chiphangwi JD, et al. Maternal vitamin A deficiency and mother-to-child transmission of HIV-1. Lancet 1994, 343:1593.
131. Brahmbhatt H, Kigozi G, Wabwire-Mengen F, et al. The effects of placental malaria on mother-to-child HIV transmission in Rakai, Uganda. AIDS 2003, 17:2539.
132. Dunn DT, Newell ML, Ades AE, et al. Risk of human immunodeficiency virus type 1 transmission through breastfeeding. Lancet 1992, 340:585.
133. Global Programme on AIDS: Consensus statement from the WHO/UNICEF consultation on HIV transmission and breast-feeding. Wkly Epidemiol Rec 1992, 7:177. World Health Organization.
134. Des Jarlais DC, Friedman SR, Choopanya K, et al. International epidemiology of HIV and AIDS among injecting drug users. AIDS 1992, 6:1053.
135. Francis HL, Quinn TC Bloodborne transmission of HIVs in Africa. AIDS in Africa 1994, 237. Raven Press, New York. M. Essex, S. Mboup, P.J. Kanki (Eds.).
136. Foster S, Buve A Benefits of HIV screening of blood transfusions in Zambia. Lancet 1995, 346:225.
137. Greenberg AE, Nguyen-Dinh P, Mann JM, et al. The association between malaria, blood transfusions, and HIV seropositivity in a pediatric population in Kinshasa, Zaire. JAMA 1988, 259:545.
138. The risk of transmission of AIDS and other blood-related diseases during routine malaria activities. Wkly Epidemiol Rec 1990, 65:345. World Health Organization.
139. Gerberding JL Management of occupational exposures to blood-borne viruses. N Engl J Med 1995, 332:444.
140. Guidelines for prevention of transmission of human immunodeficiency virus and hepatitis B virus to health-care and public-safety workers. MMWR 1989, 38(suppl 6):1.
141. Human immunodeficiency virus transmission in household settings-U.S. MMWR 1994, 43:347.
142. Friedland GH, Klein RS Transmission of the human immunodeficiency virus. N Engl J Med 1987, 317:1125.
143. Mann JM, Quinn TC, Francis H, et al. Prevalence of HTLV-III/LAV in household contacts of confirmed AIDS patients and controls in Kinshasa, Zaire. JAMA 1986, 256:721.
144. Clerici M, Giorgi JV, Chou C-C, et al. Cell-mediated immune response to human immunodeficiency virus (HIV) type 1 in seronegative homosexual men with recent sexual exposure to HIV-1. J Infect Dis 1992, 165:1012.
145. Rowland-Jones S, Sutton J, Ariyoshi K, et al. GIV-specific CTL in HIV-exposed but uninfected Cambodian women. Nature Med 1995, 1:59.
146. Phillips DM, Zacharopoulos VR, Tan X, et al. Mechanisms of sexual transmission of HIV: does HIV infect intact epithelia?. Trends Microbiol 1994, 2:454.
147. Miller CJ, Alexander NJ, Sutjipto S, et al. Genital mucosal transmission of simian immunodeficiency virus: animal model for heterosexual transmission of human immunodeficiency virus. J Virol 1989, 63:4277.
148. Kreiss JK, Coombs R, Plummer F, et al. Isolation of human immunodeficiency virus from genital ulcers in Nairobi prostitutes. J Infect Dis 1989, 160:380.
149. Cook LS, Koutsky LA, Holmes KK Circumcision and sexually transmitted diseases. Am J Public Health 1994, 84:197.
150. Osmond D, Bacchetti P, Chaisson RE, et al. Time of exposure and risk of HIV infection in homosexual partners of men with AIDS. Am J Public Health 1988, 78:944.
151. Wolinsky SM, Wike CM, Korber BTM, et al. Selective transmission of human immunodeficiency virus type-1 variants from mothers to infants. Science 1992, 255:1134.
152. Laga M, Taelman H, Van der Stuyft P, et al. Advanced immunodeficiency as a risk factor for heterosexual transmission of HIV. AIDS 1989, 3:361.
153. Wolfs TFW, Zwart G, Bakker M, et al. HIV-1 genomic RNA diversification following sexual and parenteral virus transmission. Virology 1992, 189:103.
154. DeCock KM, Adjorlolo G, Ekepni E, et al. Epidemiology of HIV-2: why there is no HIV-2 pandemic. JAMA 1993, 270:2083.
155. Robertson DL, Sharp PM, McCutchan FE, et al. Recombination in HIV-1. Nature 1995, 374:125.
156. Sharp PM, Robertson DL, Hahn BH Cross-species transmission and recombination of AIDS viruses. Philos Trans R Soc Lond B Biol Sci 1995, 349:41.
157. Travers K, Mboup S, Marlink R, et al. Natural protection against HIV-1 infection provided by HIV-2. Science 1995, 268:1612.
158. Soto-Ramirez LE, Renjifo B, McLane MF, et al. HIV-1 Langerhans cell tropism associated with heterosexual transmission of HIV. Science 1996, 271:1291.
159. Kunanusont C, Foy HM, Kreiss JK, et al. HIV-1 subtypes and male-to-female transmission in Thailand. Lancet 1995, 345:1078.
160. Decosas J, Kane F, Anarfi JK, et al. Migration and AIDS. Lancet 1995, 346:826.
161. Cameron DW, Simonsen JN, D'Costa LJ, et al. Female-to-male transmission of human immunodeficiency virus type 1: risk factors for seroconversion in men. Lancet 1989, 2:403.
162. Bongaarts J, Reining P, Way P, et al. The relationship between male circumcision and HIV infection in African populations. AIDS 1989, 3:373.
163. AIDS Epidemic Update December 2003 2003, UNAIDS, UNAIDS, Geneva.
164. Report on the global HIV/AIDS epidemic 2002 2002, UNAIDS, UNAIDS, Geneva.
165. Reynolds SJ, Shepherd ME, Risbud AR, et al. Male circumcision and risk of HIV-1 and other sexually transmitted infections in India. Lancet 2004, 363:1039.
166. Gray RH, Wawer MJ, Brookmeyer R, et al. Probability of HIV-1 transmission per coital act in monogamous, heterosexual, HIV-1-discordant couples in Rakai, Uganda. Lancet 2001, 357:1149.
167. Gray RH, Kiwanuka N, Quinn TC, et al. Male circumcision and HIV acquisition and transmission: cohort studies in Rakai, Uganda. Rakai Project Team. AIDS 2000, 14:2371.
168. Quinn TC Epidemiology of the HIV/AIDS epidemic. Preventing and Mitigating AIDS in Sub-Saharan Africa 1996, 269. National Academy Press, Washington, D.C. B. Cohen, J. Trussell (Eds.).
169. Final Report. Cosponsored by AIDS Control and Prevention (AIDSCAP) Project of Family Health International and the Francois-Xavier Bagnoud Center for Health and Human Rights of the Harvard School of Public Health 1996, Workshop on the Status and Trends of the HIV/AIDS Epidemics in Africa, Harvard School of Public Health, Cambridge, Mass.
170. Marlink R Biology and epidemiology of HIV-2. AIDS in Africa 1994, 47. Raven Press, New York. M. Essex, M. Kalengaly, P. Kanki (Eds.).
171. Markovitz DM Infection with the human immunodeficiency virus type 2. Ann Intern Med 1993, 118:211.
172. DeCock KM, Brun-Vezinet F Epidemiology of HIV-2 infection. AIDS 1989, 3(suppl 1):S89.
173. Kanki P Biologic features of HIV-2: an update. AIDS Clin Rev 1991, 17.
174. Jaffar S, Grant AD, Whitworth J, et al. The natural history of HIV-1 and HIV-2 infections in adults in Africa: a review of the literature. Bull WHO 2004, 82:462.
175. Kanki PJ, Travers KU, Mboup S, et al. Slower heterosexual spread of HIV-2 than HIV-1. Lancet 1994, 343:943.
176. Adjorlolo-Johnson G, DeCock KM, Ekpini E, et al. Prospective comparison of mother-to-child transmission of HIV-1 and HIV-2 in Abidjan, Ivory Coast. JAMA 1994, 272:462.
177. Chaisson RE HIV becomes world's leading infectious cause of death. Hopkins HIV Rep 1999, 11:1.
178. DeCock KM, Barrere B, Diaby L, et al. AIDS-The leading cause of adult death in the West African city of Abidjan, Ivory Coast. Science 1990, 1249:793.
179. Mulder DW, Nunn AJ, Kamali A Two-year HIV-1-associated mortality in a Ugandan rural population. Lancet 1994, 343:1021.
180. Sewankambo NK, Wawer MJ, Gray RH, et al. Demographic impact of HIV infection in rural Rakai District, Uganda: results of a population-based cohort study. AIDS 1994, 8:170.
181. Chin HJ Current and future dimensions of the HIV/AIDS pandemic in women and children. Lancet 1990, 336:221.
182. Dondero TJ, Curran JW Excess deaths in Africa from HIV: confirmed and quantified. Lancet 1995, 343:989.
183. Preble EA Impact of HIV/AIDS on African children. Soc Sci Med 1990, 31:671.
184. DeCock KM, Soro B, Coulibaly I-M, et al. Tuberculosis and HIV infection in sub-Saharan Africa. JAMA 1992, 268:1581.
185. Brown T, Sittirai W, Vanichseni S, et al. The recent epidemiology of HIV and AIDS in Thailand. AIDS 1994, 8(suppl 2):S131.
186. Gangakhedkar RR, Bentley ME, Divikar AD, et al. Spread of HIV infection in married monogamous women in India. JAMA 1997, 278:2090.
187. Kitayaporn D, Uneklabh C, Weniger BG, et al. HIV-1 incidence determined retrospectively among drug users in Bangkok, Thailand. AIDS 1994, 8:1443.
188. Naik TN, Sarkar S, Singh HL, et al. Intravenous drug users: a new high-risk group for HIV infection in India. AIDS 1991, 5:117.
189. Bollinger RC, Tripathy SP, Quinn TC The human immunodeficiency virus epidemic in India. Medicine (Baltimore) 1995, 74:97.
190. Cheng H, Zhang J, Capizzi J, et al. Introduction of HIV-1 subtype E into Yunnan, China. Lancet 1994, 344:953.
191. Weniger BG, Takebe Y, Ou C-Y, et al. The molecular epidemiology of HIV in Asia. AIDS 1994, 8(suppl 2):S13.
192. Rodrigues JJ, Mehendale SM, Shepherd ME, et al. The biological and behavioral risk factors for prevalent HIV infection in sexually transmitted disease clinics in India. BMJ 1995, 311:283.
193. Mehendale SM, Rodrigues JJ, Brookmeyer RS, et al. Incidence and predictors of human immunodeficiency virus type 1 seroconversion in patients attending sexually transmitted diseases clinics in India. J Infect Dis 1995, 172:1486.
194. Go VF, Srikrishnan AK, Savaram S, et al. High HIV prevalence and risk behaviors in men who have sex with men in Chennai, India. J Acquir Immune Defic Syndr 2004, 35:314.
195. Harries AD Tuberculosis and human immunodeficiency virus infection in developing countries. Lancet 1990, 335:387.
196. Jain MK, John TJ, Keusch GT A review of human immunodeficiency virus infection in India. J Acquir Immune Defic Syndr Hum Retrovirol 1994, 7:1185.
197. Kaur A, Babu PG, Jacob M, et al. Clinical and laboratory profile of AIDS in India. J Acquir Immune Defic Syndr Hum Retrovirol 1992, 5:883.
198. Tripathy SP Tuberculosis and AIDS. Indian J Tuberc 1991, 38:49.
199. Swasdisevi A Clinical study of HIV disease in the lower area of northern Thailand in 1994. J Med Assoc Thai 1994, 77:440.
200. Cohen J HIV in Asia: Myanmar. Science 2003, 301:5640.
201. Cohen J HIV/AIDS in China. Science 2004, 304:5676.
202. Wei X, Chosh SK, Taylor ME, et al. Viral dynamics in human immunodeficiency virus type 1 infection. Nature 1995, 373:117.
203. Ho DD, Neumann AU, Perelson AS, et al. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995, 373:123.
204. Graziosi C, Pantaleo G, Butini L, et al. Kinetics of HIV DNA and RNA synthesis during primary HIV-1 infection. Proc Natl Acad Sci USA 1993, 90:6505.
205. Cooper DA, Gold JA, MacLean P, et al. Acute retrovirus infection: definition of a clinical illness associated with seroconversion. Lancet 1985, 1:137.
206. Tindall B, Barker S, Donovan B, et al. Characterization of the acute clinical illness associated with human immunodeficiency virus infection. Arch Intern Med 1988, 148:945.
207. Pantaleo G, Menzo S, Vaccarezza M, et al. Studies in subjects with long-term nonprogressive human immunodeficiency virus infection. N Engl J Med 1995, 332:209.
208. Baltimore D Lessons from people with nonprogressive HIV infection. N Engl J Med 1995, 322:259.
209. Cao Y, Qin L, Zhang L, et al. Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type 1 infection. N Engl J Med 1995, 322:201.
210. Anzala OA, Nagelkerke NJ, Bwayo JJ, et al. Rapid progression to disease in African sex workers with human immunodeficiency virus type 1 infection. J Infect Dis 1995, 171:686.
211. Korchhoff F, Greenough TC, Brettler DB, et al. Brief report: absence of intact nef sequences in a long-term survivor with nonprogressive HIV-1 infection. N Engl J Med 1995, 332:228.
212. Saal F, Sidibe S, Alves-Cardoso E, et al. Anti-HIV-2 serological screening in Portuguese populations native from or having had close contact with Africa. AIDS Res Hum Retroviruses 1987, 3:341.
213. Hu DJ, Dondero TJ, Rayfield MA, et al. The emerging genetic diversity of HIV. JAMA 1996, 275:210.
214. Ameisen JC, Capron A Cell dysfunction and depletion in AIDS: the programmed cell death hypothesis. Immunol Today 1991, 12:102.
215. Groux H, Torpier G, Monte D, et al. Activation-induced death by apoptosis I CD4_ cells from human immunodeficiency virus-infected asymptomatic individuals. J Exp Med 1992, 175:331.
216. Sheppard HW, Ascher MS, McRae B, et al. The initial immune response to HIV and immune system activation determine the outcome of HIV disease. J Acquir Immune Defic Syndr Hum Retrovirol 1991, 4:704.
217. Haynes BF, Panteleo G, Fauci AS Towards an understanding of the correlates of protective and immunity to HIV infection. Science 1996, 271:324.
218. Burke DS Human HIV vaccine trials: does antibody-dependent enhancement pose a genuine risk?. Perspect Biol Med 1992, 35:511.
219. Mascola JR, Mathieson BJ, Zack PH, et al. Summary report: workshop on the potential risks of antibody-dependent enhancement in human HIV vaccine trials. AIDS Res Hum Retroviruses 1993, 9:1175.
220. Koup RA, Safrit JT, Cao Y, et al. Temporal association of cellular immune responses with the initial control of viremia in primary human
221. Borrow P, Lewicki H, Hahn BH, et al. Virus-specific CD8- cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J Virol 1994, 68:6103.
222. Paul WE Can the immune response control HIV infection?. Cell 1995, 82:177.
223. Bryson YJ, Pang S, Wei LS, et al. Clearance of HIV infection in a perinatally infected infant. N Engl J Med 1995, 332:833.
224. Shafferman A, Jahrling PB, Benveniste RE, et al. Protection of macaques with a simian immunodeficiency virus envelope peptide vaccine based on conserved human immunodeficiency virus type 1 sequences. Proc Natl Acad Sci USA 1991, 88:7126.
225. Embretson J, Zupancic M, Ribas JL, et al. Massive covert infection of helper T lymphocytes and macrophages by HIV during the incubation period of AIDS. Nature 1993, 362:359.
226. Smith KJ, Skelton HG, Yeager J, et al. Clinical features of inflammatory dermatoses in human immunodeficiency virus type 1 disease and their correlation with Walter Reed stage. J Am Acad Dermatol 1993, 28:167.
227. Valle S-L Dermatologic findings related to human immunodeficiency virus infection in high-risk individuals. J Am Acad Dermatol 1987, 17:951.
228. Feigal DW, Katz MH, Greenspan D, et al. The prevalence of oral lesions in HIV-infected homosexual and bisexual men: three San Francisco epidemiology cohorts. AIDS 1991, 5:519.
229. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR 1992, 41:1.
230. Albrecht H Redefining AIDS: Towards a modification of the current AIDS case definition. Clin Infect Dis 1997, 24:64.
231. Greenberg AE, Nsa W, Ryder RW, et al. Plasmodium falciparum malaria and perinatally acquired human immunodeficiency virus type 1 infection in Kinshasa, Zaire: A prospective, longitudinal cohort study of 587 children. N Engl J Med 1991, 325:105.
232. Pepin J, Ethier L, Kazadi C, et al. The impact of human immunodeficiency virus infection on the epidemiology and treatment of Trypanosoma brucei gambiense sleeping sickness in Nioki, Zaire. Am J Trop Med Hyg 1992, 47:133.
233. Kaplan JE, Hu DJ, Holmes HK, et al. Preventing opportunistic infections in HIV infected persons: implications for the developing world. Am J Trop Med Hyg 1996, 55:1.
234. Lucas SB, DeCock KM, Hounnou A, et al. Contribution of tuberculosis to slim disease in Africa. BMJ 1994, 308:1531.
235. Loussert-Ajakka I, Ly TD, Chaix ML, et al. HIV-1/HIV-2 seronegativity in HIV-1 subtype O infected patients. Lancet 1994, 343:1393.
236. Schable C, Zekeng L, Pau C-P, et al. Sensitivity of United States HIV antibody tests for detection of HIV-1 group O infections. Lancet 1994, 344:1333.
237. Interpretation and use of the Western blot assay for serodiagnosis of human immunodeficiency virus type 1 infections. MMWR 1989, 38:1.
238. Midthun K, Garrison L, Clements ML, et al. Frequency of indeterminate Western blot tests in healthy adults at low risk for human immunodeficiency virus infection. J Infect Dis 1990, 162:1379.
239. Genesca J, Shih JW, Jett B, et al. What do Western blot indeterminate patterns for human immunodeficiency virus mean in EIA-negative blood donors?. Lancet 1989, 2:1023.
240. Hausler WJ Report of the Third Consensus Conference on HIV Testing sponsored by the Association of State and Territorial Public Health Laboratory Directors. Infect Control Hosp Epidemiol 1988, 9:345.
241. Burke DS, Fowler AK, Redfield RR, et al. Isolation of HIV-1 from the blood of seropositive adults: patient stage of illness and sample inoculum size are major determinants of positive culture. AIDS 1990, 3:1159.
242. Dewar RL, Sarmiento MD, Lawton ES, et al. Isolation of HIV-1 from plasma of infected individuals: an analysis of experimental conditions affecting successful virus propagation. J Acquir Immune Defic Syndr Hum Retrovirol 1992, 5:822.
243. Eyster ME, Ballard JO, Gail MH, et al. Predictive markers for the acquired immunodeficiency syndrome (AIDS) in hemophiliacs: persistence of p24 antigen and low T4 cell count. Ann Intern Med 1989, 110:963.
244. Hofmann B, Bygbjerg I, Dickmeiss E, et al. Prognostic value of immunologic abnormalities and HIV antigenemia in asymptomatic HIV-infected individuals: proposal of immunologic staging. Scand J Infect Dis 1989, 21:633.
245. Nishanian P, Huskins KR, Stehn S, et al. A simple method for improved assay demonstrates that HIV p24 antigen is present as immune complexes in most sera from HIV-infected individuals. J Infect Dis 1990, 162:21.
246. Kestens L, Hoofd G, Gigase PI, et al. HIV antigen detection in circulating immune complexes. J Virol Methods 1991, 31:67.
247. Ou CY, Kwok S, Mitchell SW, et al. DNA amplification for direct detection of HIV-1 in DNA of peripheral blood mononuclear cells. Science 1988, 239:295.
248. Bagnarelli P, Menzo S, Manzin A, et al. Detection of human immunodeficiency virus type 1 genomic RNA in plasma samples by reverse transcription-polymerase chain reaction. J Med Virol 1991, 34:89.
249. Menzo S, Bagnarelli P, Giacca M, et al. Alsolute quantitation of viremia in human immunodeficiency virus infection by competitive reverse transcription and polymerase chain reaction. J Clin Microbiol 1992, 30:1752.
250. Dewar RL, Highbarger HC, Sarmiento MD, et al. Application of branched DNA signal amplification to monitor human immunodeficiency virus type 1 burden in human plasma. J Infect Dis 1994, 170:1172.
251. Wong MT, Dolan MJ, Kozlow E, et al. Patterns of virus burden and T-cell phenotype are established early and are correlated with the rate of disease progression in human immunodeficiency virus type 1-infected persons. J Infect Dis 1996, 173:877.
252. Lin HJ, Myers LE, Yen-Leiberman E, et al. Multicenter evaluation of quantification methods for plasma human immunodeficiency virus type 1 RNA. J Infect Dis 1994, 170:553.
253. Moss AR, Bacchetti P, Osmond D, et al. Seropositivity for HIV and the development of AIDS or AIDS-related condition: three year follow up of the San Francisco General Hospital Cohort. BMJ 1988, 296:745.
254. Goedert JJ, Kessler CM, Aledort LM, et al. A prospective study of human immunodeficiency virus type 1 infection and the development of AIDS in subjects with hemophilia. N Engl J Med 1989, 321:1141.
255. Redfield RR, Wright DC, Tramont EC The Walter Reed staging system for HTLV-III/LAV infection. N Engl J Med 1986, 31:314.
256. McLeod G, Hammer S Zidovudine: Five years later. Ann Intern Med 1992, 117:487.
257. Volberding PA, Lagakos SW, Koch MA, et al. Zidovudine in asymptomatic human immunodeficiency virus infection: a controlled trial in persons with fewer than 500 CD4 positive cells per cubic millimeter. N Engl J Med 1990, 322:941.
258. Johnson V Nucleoside reverse transcriptase inhibitors and resistance of human immunodeficiency virus type 1. J Infect Dis 1995, 17(suppl):S140.
259. Saag M, Emini E, Laskin O, et al. A short-term clinical evaluation of L-697,661, a non-nucleoside inhibitor of HIV-1 reverse transcriptase. N Engl J Med 1993, 329:1065.
260. Sande M, Carpenter C, Cobbs C, et al. Antiretroviral therapy for adult HIV infected patients: recommendations from a state-of-the-art conference. JAMA 1994, 271:1830.
261. Miller M, Jaskolski M, Rao JKM, et al. Crystal structure of a retroviral protease proves relationship to aspartic protease family. Nature 1989, 337:576.
262. Wlodawer A, Erickson JW Structure based inhibitors of HIV-1 protease. Annu Rev Biochem 1993, 62:543.
263. Raguin G, Chene G, Mourand-Joubert L, et al. for the Puzzle 1 Study Group: Salvage therapy with amprenavir, lopinavir, and ritonavir 200 mg/d or 400 mg/d in HIV-infected patients in virological failure. Antivir Ther 2004, 9:615.
264. Johnson M, Grinsztejn B, Rodriguez C, et al. Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures. AIDS 2005, 19:685.
265. Pomerantz RJ, Horn DL Twenty years of therapy for HIV-1 infection. Nature Med 2003, 9:867.
266. Lane HC, Davey V, Kovacs JA, et al. Interferon-alpha in patients with asymptomatic human immunodeficiency virus (HIV) infection: a randomized, placebo-controlled trial. Ann Intern Med 1990, 112:805.
267. Groopman JE, Gottlieb MS, Goodman J, et al. Recombinant alpha-2 interferon therapy for Kaposi's sarcoma associated with the acquired immunodeficiency syndrome. Ann Intern Med 1984, 100:671.
268. Kovacs JA, Baseler M, Dewar RJ, et al. Increases in CD4 T lymphocytes with intermittent courses of interleukin-2 in patients with human immunodeficiency virus infection: a preliminary study. N Engl J Med 1995, 332:567.
269. Yeni PG, Hammer SM, Hirsch MS, et al. Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society- USA panel. JAMA 2004, 292:2.
270. Carpenter CJ, Fishl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1998: updated recommendations of the International AIDS Society-USA panel. JAMA 1998, 280:78.
271. Richman DD Resistance of clinical isolates of human immunodeficiency virus to antiretroviral agents. Antimicrob Agents Chemother 1993, 37:1207.
272. Condra JH, Schleif WA, Blahy OM, et al. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature 1995, 374:569.
273. Huang H, Chopra R, Verdine GL, Harrison SC Structure of a covalently trapped catalytic complex of HIV-1 reverse transcriptase: implications for drug resistance. Science 1998, 282:1669.
274. Sarafianos SG, Das K, Clark AD, et al. Lamivudine (3TC) resistance in HIV-1 reverse transcriptase involves steric hindrance with beta-branched amino acids. Proc Natl Acad Sci USA 1999, 96:10027.
275. Doyon L, Croteau G, Thibeault D, et al. Second locus involved in human immunodeficiency virus type 1 resistance to protease inhibitors. J Virol 1996, 70:3763.
276. Zhang YM, Imamichi H, Imamichi T, et al. Drug resistance during indinavir therapy is caused by mutations in the protease gene and in its Gag substrate cleavage sites. J Virol 1997, 71:6662.
277. Cote HC, Brumme ZL, Harrigan PR Human immunodeficiency virus type 1: protease cleavage site mutations associated with protease inhibitor cross-resistance selected by indinavir, ritonavir, and/or saquinavir. J Virol 2001, 75:589.
278. Erickson JW, Gulnik SV, Markowitz M Protease inhibitors: resistance, cross-resistance, fitness and the choice of initial and salvage therapies. AIDS 1999, 13(suppl A):S189.
279. Miller V Resistance to protease inhibitors. J Acquir Immune Defic Syndr 2001, 26(suppl 1):S34.
280. Deng Z, Ribas JL, Gibson DW, et al. Infections caused by Penicillium marneffei in China and Southeast Asia: review of eighteen published cases and report of four more Chinese cases. Rev Infect Dis 1988, 10:640.
281. Fischl MA, Dickinson GM, LaVoie L Safety and efficacy of sulfamethoxazole and trimethoprim chemoprophylaxis for Pneumocystis carinii pneumonia in AIDS. JAMA 1988, 259:1185.
282. Chintu C, Bhat GJ, Walker AS, et al. Co-trimoxazole as prophylaxis against opportunistic infections in HIV-infected Zambian children (CHAP): a double-blind randomised placebo-controlled trial. Lancet 2005, 365:749.
283. Mermin J, Lule J, Ekwaru JP, et al. Effect of co-trimoxazole prophylaxis on morbidity, mortality, CD4-cell count, and viral load in HIV infection in rural Uganda. Lancet 2004, 364:1428.
284. Masur H, Kaplan JE, Holmes KK USPHS/IDSA guidelines for preventing opportunistic infections-2002. Recommendations of the US Public Health Service and the Infectious Disease Society of America. Ann Intern Med 2002, 137:435.
285. Pape JW, Jean SS, Ho JL, et al. Effect of isoniazid prophylaxis on incidence of active tuberculosis and progression of HIV infection. Lancet 1993, 342:268.
286. DeCock KM, Grant A, Porter JD Preventive therapy for tuberculosis in HIV-infected persons: international recommendations, research, and practice. Lancet 1995, 345:833.
287. Higgins DL, Galavotti C, O'Reilly KR, et al. Evidence for the effects of HIV antibody counseling and testing on risk behaviors. JAMA 1991, 266:2419.
288. McCusker J, Stoddard AM, Mayer KH, et al. Effects of HIV antibody test knowledge on subsequent sexual behaviors in a cohort of homosexually active men. Am J Public Health 1988, 78:462.
289. Otten MW, Zaida AA, Wroten JE, et al. Changes in sexually transmitted disease rates after HIV testing and posttest counseling, Miami, 1988 to 1989. Am J Public Health 1993, 83:529.
290. Kelly JA, Murphy DA, Sikkema KJ, et al. Psychological interventions to prevent HIV infection are urgently needed: new priorities for behavioral research in the second decade of AIDS. Am Psychol 1993, 48:1023.
291. Kelly JA, St.Lawrence JS, Hood HV, et al. Behavioral intervention to reduce AIDS risk activities. J Consult Clin Psychol 1989, 57:60.
292. Des Jarlais DC, Friedman SR AIDS and the use of injected drugs. Sci Am 1994, 270:82.
293. Walker MC, Fast PE, Graham B, et al. Phase I/II preventive vaccine trials. AIDS Res Hum Retroviruses 1995, 11:1279.
294. Burke DS Review: Human trials of experimental HIV vaccines. AIDS 1995, 9(suppl):S171.
295. Funds Committed and Dispersed. Geneva, Global Fund to Fight AIDS, Tuberculosis and Malaria, 2004. Available at. http://www.theglobalfund.org.
296. Bush GW: State of the Union address, January 28, 2003. Available at. Accessed 10/04/04. http://www.whitehouse.gov/news/releases/2003/01/20030128-19.html.
297. Teixeira PR, Vitoria MA, Barcarolo J Antiretroviral treatment in resource-poor settings: the Brazilian experience. AIDS 2004, 18(suppl 3):S5.
298. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Rockville, Md., Department of Health and Human Services, October 29, 2004. Available at. Accessed 11/01/04. http://www.aidsinfo.nih.gov/guidelines/adult/AA_102904.pdf.
299. Florence E, Dreezen C, Schrooten W, et al. The role of non-viral load surrogate markers in HIV-positive patient monitoring during antiviral treatment. Int J STD AIDS 2004, 8:538.
300. Adje C, Cheingson R, Roels TH, et al. High prevalence of genotypic and phenotypic HIV-1 drug-resistant strains among patients receiving antiretroviral therapy in Abidjan, Côte d'Ivoire. J Acquir Immune Defic Syndr 2001, 26:501.
301. Vergne L, Malonga-Mouellet G, Mistoul I, et al. Resistance to antiretroviral treatment in Gabon: need for implementation of guidelines on antiretroviral therapy use and HIV-1 drug resistance monitoring in developing countries. J Acquir Immune Defic Syndr 2002, 29:165.
302. Richard N, Juntilla M, Abraha A, et al. High prevalence of antiretroviral resistance in treated Ugandans infected with non-subtype B human immunodeficiency virus type 1. AIDS Res Hum Retroviruses 2004, 20:355.
303. Koenig SP, Leandre F, Farmer PE, et al. Scaling-up HIV treatment programmes in resource-limited settings: the rural Haiti experience. AIDS 2004, 18(suppl 3):S21.
304. Teixeira PR, Vitoria MA, Barcarolo J: Antiretroviral treatment in resource-poor settings: the Brazilian experience. AIDS, 18 (suppl 3):S5.
305. Praphan P Antiretroviral treatment in resource-poor settings: what can we learn from the existing programs in Thailand?. AIDS 2004, 18(suppl 3):S33.
306. Weidle PJ, Malamba S, Mwebaze R, et al. Asessment of a pilot antiretroviral drug therapy programme in Uganda: patients' response, survival, and drug resistance. Lancet 2002, 360:34.
307. Laurent C, Diakhate N, Gueye NF, et al. The Senegalese government's highly active antiretroviral therapy initiative: an 18-month follow-up study. AIDS 2002, 16:1363.
308. Coetzee D, Boulle A, Hildebrand K, et al. Promoting adherence to antiretroviral therapy: the experience from a primary care setting in Khayelitsha, South Africa. AIDS 2004, 18(suppl 3):S27.
309. Badri M, Wilson D, Wood R Effect of highly active antiretroviral therapy on incidence of tuberculosis in South Africa: a cohort study. Lancet 2002, 359:2059.